Amanda L Marzo

Dr. Amanda L Marzo

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
KGKajal Gupta
Kajal Gupta
CNChristina Nowicki
Christina Nowicki
EGEileena Giurini
Eileena Giurini
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
Andrew ZlozaAndrew Zloza
Andrew Zloza
Currently approximately 10 million people die each year due to cancer, and cancer is the cause of every sixth death worldwide. Tremendous efforts and progress have been made towards finding a cure for cancer. However, numerous challenges have been faced due to adverse effects of chemotherapy, radiotherapy, and alternative cancer therapies, including toxicity to non-cancerous cells, the inability of drugs to reach deep tumor tissue, and the persistent problem of increasing drug resistance in tumor cells. These challenges have increased the demand for the development of alternative approaches with greater selectivity and effectiveness against tumor cells. Cancer immunotherapy has made significant advancements towards eliminating cancer. Our understanding of cancer-directed immune responses and the mechanisms through which immune cells invade tumors have extensively helped us in the development of new therapies. Among immunotherapies, the application of bacteria and bacterial-based products has promising potential to be used as treatments that combat cancer. Bacterial targeting of tumors has been developed as a unique therapeutic option that meets the ongoing challenges of cancer treatment. In comparison with other cancer therapeutics, bacterial-based therapies have capabilities for suppressing cancer. Bacteria are known to accumulate and proliferate in the tumor microenvironment and initiate antitumor immune responses. We are currently well-informed regarding various methods by which bacteria can be manipulated by simple genetic engineering or synthetic bioengineering to induce the production of anti-cancer drugs. Further, bacterial-based cancer therapy (BBCT) can be either used as a monotherapy or in combination with other anticancer therapies for better clinical outcomes. Here, we review recent advances, current challenges, and prospects of bacteria and bacterial products in the development of BBCTs.

1 September 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RSRyan T. Sowell
Ryan T. Sowell
MRMagdalena Rogozinska
Magdalena Rogozinska
CNChristine E Nelson
Christine E Nelson
VVVaiva Vezys
Vaiva Vezys
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
Mucosal tissues are subject to frequent pathogen exposure and are major sites for transmission of infectious disease. CD8 T cells play a critical role in controlling mucosa-acquired infections even though their migration into mucosal tissues is tightly regulated. The mechanisms and signals that control the formation of tissue-resident memory CD8 T cells are poorly understood; however, one key regulator of memory CD8 T cell differentiation, mammalian target of rapamycin kinase, can be inhibited by rapamycin. We report that, despite enhancing the formation of memory CD8 T cells in secondary lymphoid tissues, rapamycin inhibits the formation of resident memory CD8 T cells in the intestinal and vaginal mucosa. The ability of rapamycin to block the formation of functional resident CD8 T cells in mucosal tissues protected mice from a model of CD8 T cell–mediated lethal intestinal autoimmunity. These findings demonstrate an opposing role for mammalian target of rapamycin in the formation of resident versus nonresident CD8 T cell immunity.

1 October 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RSRyan T. Sowell
Ryan T. Sowell
JGJosef W. Goldufsky
Josef W. Goldufsky
MRMagdalena Rogozinska
Magdalena Rogozinska
ZQZurisaday Quiles
Zurisaday Quiles
YCYanxia Cao
Yanxia Cao
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
IL-15 is an essential cytokine known to promote T cell survival and activate the effector function of memory phenotype CD8 T cells. Blocking IL-15 signals also significantly impacts tissue-specific effector and memory CD8 T cell formation. In this study, we demonstrate that IL-15 influences the generation of memory CD8 T cells by first promoting their accumulation into mucosal tissues and second by sustaining expression of Bcl-6 and T-bet. We show that the mechanism for this recruitment is largely dependent on mammalian target of rapamycin and its subsequent inactivation of FoxO1. Last, we show that IL-15 complexes delivered locally to mucosal tissues without reinfection is an effective strategy to enhance establishment of tissue resident memory CD8 T cells within mucosal tissues. This study provides mechanistic insight into how IL-15 controls the generation of memory CD8 T cells and influences their trafficking and ability to take up residence within peripheral tissues.

Verified
Journal Article
Open access
PDF file
MLMalia Elisabeth Leifheit
Malia Elisabeth Leifheit
GJGunnar James Johnson
Gunnar James Johnson
TKTimothy M. Kuzel
Timothy M. Kuzel
JSJeffrey Schneider
Jeffrey Schneider
EBEdward Barker
Edward Barker
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML represent a challenging clinical scenario characterized by a high rate of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The advent of FLT3 tyrosine kinase inhibitors (TKIs), such as midostaurin and gilteritinib, has shown promise in achieving complete remission. However, a substantial proportion of patients still experience relapse following TKI treatment, necessitating innovative therapeutic strategies. This review critically addresses the current landscape of TKI treatments for FLT3+ AML, with a particular focus on gilteritinib. Gilteritinib, a highly selective FLT3 inhibitor, has demonstrated efficacy in targeting the mutant FLT3 receptor, thereby inhibiting aberrant signaling pathways that drive leukemic proliferation. However, monotherapy with TKIs may not be sufficient to eradicate AML blasts. Specifically, we provide evidence for integrating gilteritinib with mammalian targets of rapamycin (mTOR) inhibitors and interleukin-15 (IL-15) complexes. The combination of gilteritinib, mTOR inhibitors, and IL-15 complexes presents a compelling strategy to enhance the eradication of AML blasts and enhance NK cell killing, offering a potential for improved patient outcomes.

5 February 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RSRyan T. Sowell
Ryan T. Sowell
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
Resident-Memory CD8 T Cells and mTOR: Generation, Protection, and Clinical Importance

1 February 2013 in OncoImmunology
Verified
Journal Article
Open access
NLNadine M. Lerret
Nadine M. Lerret
Amanda L MarzoAmanda L Marzo
Amanda L Marzo
The major objectives of tumor vaccination are to induce the regression of established tumors and to favor the establishment of long-lasting tumor-specific immunity, capable of protecting the host f...